Latest News

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 10.9% year on year to $706.8 million. The company’s full-year revenue guidance of $3.10 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP loss of $0.21 per share was significantly below analysts’ consensus estimates.

Infrastructure construction company MasTec (NYSE:MTZ) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 6% year on year to $2.85 billion. On top of that, next quarter’s revenue guidance ($3.4 billion at the midpoint) was surprisingly good and 4.4% above what analysts were expecting. Its non-GAAP profit of $0.51 per share was 51.2% above analysts’ consensus estimates.

Professional consulting firm ICF International (NASDAQ:ICFI) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.4% year on year to $487.6 million. Its non-GAAP profit of $1.94 per share was 12.1% above analysts’ consensus estimates.

Temporary space provider WillScot (NASDAQ:WSC) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 4.7% year on year to $559.6 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $2.38 billion at the midpoint. Its non-GAAP profit of $0.24 per share was 11.1% below analysts’ consensus estimates.

Infrastructure consulting firm NV5 Global (NASDAQ:NVEE) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.1% year on year to $234 million. The company’s full-year revenue guidance of $1.04 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.17 per share was 8.9% below analysts’ consensus estimates.

Medical technology company Hologic (NASDAQ:HOLX) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.2% year on year to $1.01 billion. On the other hand, next quarter’s revenue guidance of $1.01 billion was less impressive, coming in 2% below analysts’ estimates. Its non-GAAP profit of $1.03 per share was 1.4% above analysts’ consensus estimates.

Scientific consulting firm Exponent (NASDAQ:EXPO) announced better-than-expected revenue in Q1 CY2025, with sales up 6% year on year to $145.5 million. On the other hand, next quarter’s revenue guidance of $130 million was less impressive, coming in 3.8% below analysts’ estimates. Its GAAP profit of $0.52 per share was 8% above analysts’ consensus estimates.

Telecommunications infrastructure company Lumen Technologies (NYSE:LUMN) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 3.3% year on year to $3.18 billion. Its non-GAAP loss of $0.13 per share was 51.2% above analysts’ consensus estimates.

Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 12% year on year to $59.87 million. Guidance for next quarter’s revenue was optimistic at $62.5 million at the midpoint, 2.2% above analysts’ estimates. Its GAAP profit of $0.48 per share was 4.6% below analysts’ consensus estimates.

Medical technology company Stryker (NYSE:SYK) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 11.9% year on year to $5.87 billion. Its non-GAAP profit of $2.84 per share was 4% above analysts’ consensus estimates.

Industrial conglomerate SPX Technologies (NYSE:SPXC) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 3.7% year on year to $482.6 million. The company’s full-year revenue guidance of $2.23 billion at the midpoint came in 3.5% above analysts’ estimates. Its non-GAAP profit of $1.38 per share was 17.6% above analysts’ consensus estimates.

Industrial manufacturer Standex (NYSE:SXI) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 17.2% year on year to $207.8 million. Its non-GAAP profit of $1.95 per share was 1.5% above analysts’ consensus estimates.

Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 20.3% year on year to $158.7 million. The company’s full-year revenue guidance of $695 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP loss of $0.95 per share was 1.5% below analysts’ consensus estimates.

Outerwear manufacturer Columbia Sportswear (NASDAQ:COLM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 1.1% year on year to $778.5 million. On the other hand, next quarter’s revenue guidance of $587.5 million was less impressive, coming in 2.9% below analysts’ estimates. Its GAAP profit of $0.75 per share was 9.7% above analysts’ consensus estimates.

Digital transformation consultancy Grid Dynamics (NASDAQ:GDYN) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 25.8% year on year to $100.4 million. The company expects next quarter’s revenue to be around $101 million, close to analysts’ estimates. Its non-GAAP profit of $0.11 per share was 24.9% above analysts’ consensus estimates.

Construction management software maker Procore (NYSE:PCOR) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 15.3% year on year to $310.6 million. On the other hand, next quarter’s revenue guidance of $311 million was less impressive, coming in 1.4% below analysts’ estimates. Its non-GAAP profit of $0.23 per share was 24.4% above analysts’ consensus estimates.

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be around $4.6 billion, close to analysts’ estimates. Its non-GAAP profit of $0.32 per share was in line with analysts’ consensus estimates.

IT project management software company, Atlassian (NASDAQ:TEAM) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 14.1% year on year to $1.36 billion. The company expects next quarter’s revenue to be around $1.35 billion, close to analysts’ estimates. Its non-GAAP profit of $0.97 per share was 4.9% above analysts’ consensus estimates.

Transmission provider Allison Transmission (NYSE:ALSN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 2.9% year on year to $766 million. On the other hand, the company’s full-year revenue guidance of $3.25 billion at the midpoint came in 2% above analysts’ estimates. Its GAAP profit of $2.23 per share was 8.7% above analysts’ consensus estimates.

Online payroll and human resource software provider Asure (NASDAQ:ASUR) announced better-than-expected revenue in Q1 CY2025, with sales up 10.1% year on year to $34.85 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $31 million was less impressive, coming in 2.2% below expectations. Its GAAP loss of $0.09 per share was 40.6% below analysts’ consensus estimates.